Pr. Zhong-Yi Dong | Oncology | Best Researcher Award

Teacher at Universidade Federal do Oeste do Pará, China

Dr. Dong Zhongyi, born in August 1985, is an esteemed oncologist specializing in tumor radiotherapy. With over a decade of experience, he serves as Associate Chief Physician in the Department of Radiotherapy at Southern Hospital, Southern Medical University. He leads the lung cancer subspecialty group and mentors postgraduate students. Dr. Dong has received numerous accolades, including recognition in the “World’s Top 2% Scientists” (2024) and the “Guangdong Special Support Plan for Young Top Talents in Health.” His research contributions include over 20 high-impact publications and multiple national patents. He has been invited to present at international and domestic conferences and has secured major research grants. Dr. Dong actively participates in academic leadership, holding key positions in multiple professional medical committees in Guangdong, China. His work significantly advances the field of oncology, particularly in radiotherapy and immunotherapy for lung cancer.

Professional Profiles

ORwID

Education

Dr. Dong Zhongyi pursued his medical education at prestigious institutions, building a strong foundation in oncology and clinical medicine. He earned his Bachelor of Clinical Medicine from the University of South China, School of Medicine (2004-2009). This early training equipped him with essential medical knowledge and clinical skills. Following his undergraduate studies, he specialized further by obtaining a Master’s degree in Oncology (2009-2012) from Southern Hospital, Southern Medical University. During this time, he developed expertise in cancer treatment and research, particularly in radiotherapy and targeted therapies. Dr.Dong then advanced his academic journey with a Ph.D. in Oncology (2014-2017) from the Lung Cancer Research Institute, Guangdong Provincial People’s Hospital, under the mentorship of Professor Yilong Wu. His doctoral research focused on the molecular mechanisms of immune resistance and tumor microenvironments, providing critical insights into cancer progression and treatment strategies. This work laid the foundation for his impactful contributions to clinical oncology and translational medicine.

Work Experience

Dr. Dong Zhongyi has built a distinguished career in oncology, marked by extensive clinical practice, research, and teaching in tumor radiotherapy. He began his professional journey as a Resident Physician (2012-2014) at Xiangtan Central Hospital, Hunan Province, where he gained hands-on experience in patient care and medical oncology. This period helped him develop a strong clinical foundation in cancer treatment. Following this, he advanced to the role of Attending Physician (2017-2022) at Southern Hospital, Southern Medical University, where he further honed his expertise in lung cancer treatment and radiotherapy. His dedication to integrating research with clinical practice significantly improved patient outcomes. Currently, Dr. Dong serves as an Associate Chief Physician (2022-Present) at Southern Hospital, Southern Medical University, where he continues to lead advancements in oncology. In addition to his clinical role, he is deeply involved in medical education, serving as a Master’s Supervisor (2021-Present) and Doctoral Supervisor (2024-Present). Throughout his career, Dr. Dong has remained at the forefront of lung cancer research, pioneering innovative treatment strategies and leading multiple research projects. His commitment to mentoring young medical professionals has played a crucial role in shaping the next generation of oncologists

Awards and Honors 🏆

Dr. Dong Zhongyi has received numerous prestigious awards in recognition of his exceptional contributions to lung cancer research and oncology. He was honored with the “Guangdong Special Support Plan for Young Top Talents in Health,” reflecting his leadership in medical research. In 2024, he was listed among the “World’s Top 2% Scientists,” a testament to his global impact in oncology. His achievements in lung cancer research were further acknowledged when he ranked 41st among China’s Top 100 Schors in Lung Cancer (2022). Additionally, he received the IASLC Developing Nation Award twice, in 2016 and 2020, highlighting his contributions to international lung cancer research. In 2020, Dr. Dong was awarded the First Prize of the Guangdong Natural Science Award, recognizing his groundbreaking work in tumor radiotherapy and cancer treatment. His dedication to advancing oncology has also been supported by prestigious talent programs, including the “National Outstanding Young Scientist Cultivation Plan (Class A)” and the “Excllent Young Scientist Cultivation Plan” by Southern Medical University. These accolades underscore Dr. Dong’s remarkable impact on the field, cementing his status as a leading researcher and clinician in lung cancer treatment and translational medicine.

Skills💡

Dr. Dong Zhongyi is a distinguished expert in oncology research and clinical application, seamlessly integrating cutting-edge research into patient care. His expertise in radiotherapy and immunotherapy has contributed to advanced cancer treatment strategies, improving therapeutic outcomes. With a strong foundation in molecular and translational medicine, he continuously innovates in tumor biology, enhancing precision oncology approaches. As a prolific researcher, Dr. Dong has authored over 20 high-impact scientific papers, demonstrating his excellence in scientific writing and publishing. His commitment to academic mentorship is evident in his role as a supervisor for postgraduate research, nurturing the next generation of oncology professionals. Additionally, his contributions to medical innovation and patents—holding multiple invention patents—underscore his role as a leader in oncology research and education. Through these skills, Dr. Dong continues to drive advancements in cancer treatment and medical science.

Research Focus 🔬

Dr. Dong Zhongyi’s research encompasses both clinical and translational oncology, with a strong focus on advancing lung cancer treatment. His work in radiotherapy and immunotherapy has led to significant advancements in treatment strategies, improving patient survival and quality of life. He has extensively investigated the molecular mechanisms of immune resistance, shedding light on how tumor microenvironments influence therapy effectiveness. Additionally, Dr. Dong has contributed to understanding and mitigating the adverse effects of immunotherapy, developing strategies to enhance patient safety and treatment efficacy. His groundbreaking research has influenced global oncology guidelines and has been cited in expert consensus documents, underscoring his role in shaping the future of cancer care. By refining precision medicine approaches, his work continues to drive innovation in oncology, ultimately improving patient outcomes worldwide.

Conclusion

Publications Top Notes

CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

Journal: Nature Communications

Year: 2023

PMID: 36871040